Literature DB >> 1964823

A series of novel, highly potent and selective agonists for the kappa-opioid receptor.

A G Hayes1, P J Birch, N J Hayward, M J Sheehan, H Rogers, M B Tyers, D B Judd, D I Scopes, A Naylor.   

Abstract

1. This paper describes the opioid receptor pharmacology and in vivo activity of several novel benzene-acetamidopiperidine and benzeneacetamidopiperazine analogues. 2. These compounds all showed potent, naloxone-reversible, full agonist activity in the field-stimulated rabbit vas deferens, indicating that they are kappa-opioid agonists; but showed very little activity in the rat or hamster vas deferens, indicating good selectivity with regard to mu- and delta-opioid receptors. 3. They were all potent antinociceptive agents, the most potent compound, GR 103545, having an ED50 value in the mouse abdominal constriction test of 0.25 micrograms kg-1 s.c. The compounds also produced sedation and diuresis, but had little effect on respiration rate or gastrointestinal motility. 4. It is concluded that the seven novel compounds described are all potent and selective agonists for the kappa-opioid receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1964823      PMCID: PMC1917842          DOI: 10.1111/j.1476-5381.1990.tb14185.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Rabbit vas deferens: a specific bioassay for opioid kappa-receptor agonists.

Authors:  T Oka; K Negishi; M Suda; T Matsumiya; T Inazu; M Ueki
Journal:  Eur J Pharmacol       Date:  1981-07-17       Impact factor: 4.432

2.  A kappa opioid effect: increased urination in the rat.

Authors:  J D Leander
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

3.  Determination of receptors that mediate opiate side effects in the mouse.

Authors:  A G Hayes; M B Tyers
Journal:  Br J Pharmacol       Date:  1983-07       Impact factor: 8.739

4.  U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

Authors:  P F Vonvoigtlander; R A Lahti; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

5.  Effects of the highly selective kappa opioid, U-50, 488, on renal function in the anesthetized dog.

Authors:  G R Slizgi; C J Taylor; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1984-09       Impact factor: 4.030

6.  Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse.

Authors:  F Porreca; H I Mosberg; R Hurst; V J Hruby; T F Burks
Journal:  J Pharmacol Exp Ther       Date:  1984-08       Impact factor: 4.030

7.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

8.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

9.  The opioid kappa-selective compound U-50,488H does not inhibit intestinal propulsion in rats.

Authors:  A Tavani; M C Gambino; P Petrillo
Journal:  J Pharm Pharmacol       Date:  1984-05       Impact factor: 3.765

10.  Effect of the opioid kappa-receptor agonist U50488H on the secretion of arginine vasopressin. Study on the mechanism of U50488H-induced diuresis.

Authors:  Y Oiso; Y Iwasaki; K Kondo; K Takatsuki; A Tomita
Journal:  Neuroendocrinology       Date:  1988-12       Impact factor: 4.914

View more
  9 in total

1.  GR94839, a kappa-opioid agonist with limited access to the central nervous system, has antinociceptive activity.

Authors:  H Rogers; P J Birch; S M Harrison; E Palmer; G R Manchee; D B Judd; A Naylor; D I Scopes; A G Hayes
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

2.  Neuroprotective actions of GR89696, a highly potent and selective kappa-opioid receptor agonist.

Authors:  P J Birch; H Rogers; A G Hayes; N J Hayward; M B Tyers; D I Scopes; A Naylor; D B Judd
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

3.  Development and In Vivo Evaluation of a κ-Opioid Receptor Agonist as a PET Radiotracer with Superior Imaging Characteristics.

Authors:  Songye Li; Ming-Qiang Zheng; Mika Naganawa; Sujin Kim; Hong Gao; Michael Kapinos; David Labaree; Yiyun Huang
Journal:  J Nucl Med       Date:  2019-01-10       Impact factor: 10.057

4.  Sensory nerve-mediated relaxation of guinea-pig isolated pulmonary artery: prejunctional modulation by alpha 2-adrenoceptor agonists but not sumatriptan.

Authors:  A Butler; S P Worton; C T O'Shaughnessy; H E Connor
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

5.  Functional evidence for multiple receptor activation by kappa-ligands in the inhibition of spinal nociceptive reflexes in the rat.

Authors:  J F Herrero; P M Headley
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

6.  Opioidergic projections to sleep-active neurons in the ventrolateral preoptic nucleus.

Authors:  Mary-Ann Greco; Patrick M Fuller; Thomas C Jhou; S Martin-Schild; James E Zadina; Zhian Hu; Priyattam Shiromani; Jun Lu
Journal:  Brain Res       Date:  2008-09-24       Impact factor: 3.252

7.  Central and peripheral actions of the novel kappa-opioid receptor agonist, EMD 60400.

Authors:  A Barber; G D Bartoszyk; H E Greiner; F Mauler; R D Murray; C A Seyfried; M Simon; R Gottschlich; J Harting; I Lues
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

8.  Synthesis and Pharmacological Evaluation of Fluorinated Quinoxaline-Based κ-Opioid Receptor (KOR) Agonists Designed for PET Studies.

Authors:  Giovanni Tangherlini; Frederik Börgel; Dirk Schepmann; Samuel Slocum; Tao Che; Stefan Wagner; Katrin Schwegmann; Sven Hermann; Nadine Mykicki; Karin Loser; Bernhard Wünsch
Journal:  ChemMedChem       Date:  2020-09-01       Impact factor: 3.466

Review 9.  A Survey of Molecular Imaging of Opioid Receptors.

Authors:  Paul Cumming; János Marton; Tuomas O Lilius; Dag Erlend Olberg; Axel Rominger
Journal:  Molecules       Date:  2019-11-19       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.